Phase I single-blind clinical trial to evaluate the safety and local immune activation of a toll-like receptor 5 agonist (FLAMOD) administered by aerosol
This is a very early study, called a Phase 1 clinical trial, which means it's the first time this new medicine (named FLAMOD) is being tested in people. The main goal is to see if FLAMOD is safe when given as a spray that you breathe in (like an asthma inhaler). Researchers also want to find out how it might kick-start the body's natural protection (immune system) in the lungs. The study focuses on people who have pneumonia, a lung infection. By understanding how FLAMOD works and if it's safe at this early stage, scientists hope to develop better ways to treat pneumonia in the future.
At a glance
What is this study about?
This study is about a new medicine called FLAMOD. It's being developed to help people with pneumonia. Pneumonia is a common lung infection that can make breathing difficult and can sometimes be serious. The researchers want to see if FLAMOD could be a new way to help your body fight off this infection.
Because this is a very new medicine, this study is considered a 'Phase 1' clinical trial. This means it's the first time FLAMOD is being given to people. The main thing the researchers are looking for is whether the medicine is safe when given as an aerosol. An aerosol means it's sprayed in a fine mist, like how some asthma medicines are taken using an inhaler. They also want to see if FLAMOD can wake up your body's natural defence system (your immune system) in your lungs to help fight the infection.
By carefully checking the safety and how your body reacts to FLAMOD, the scientists hope to gather important information. This information will help them decide if FLAMOD has the potential to become a helpful treatment for pneumonia in the future. It's a key first step in developing new medicines.
Key takeaways
- This is an early-stage study for a new pneumonia medicine called FLAMOD.
- It's the first time FLAMOD is being tested in people.
- Its main purpose is to check for safety when given as an inhaled spray.
- Researchers also want to see how it affects the body's natural defences in the lungs.
- The study is for adults (18 years and older) with pneumonia.
Who may be eligible?
To be able to take part in this study, you would need to be an adult, 18 years old or older. There is no upper age limit, so people of all adult ages can be considered. The study is open to both men and women.
Beyond basic age and sex, specific health conditions or medications you are taking might affect whether you can participate. This is because the researchers need to make sure the study gathers clear information about the new medicine without other health issues making it difficult to understand the results.
If you're interested in joining, the study team would carefully review your medical history and current health to see if it's a good fit for you. They will explain all the specific requirements in detail.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years of age or older?
- Have you been diagnosed with pneumonia?
- Are you able to attend regular study appointments?
- Are you willing to potentially receive a new medicine or a dummy treatment?
What does participation involve?
If you decide to take part, you would receive the study medicine, FLAMOD, as an aerosol, which means you would breathe it in, similar to using an inhaler. During the study, you would need to attend several visits at the study clinic. These visits are important for the team to monitor your health and how you react to the medicine.
During these visits, the study team will carry out various checks and assessments, including physical examinations, blood tests, and perhaps some lung tests, to make sure you are safe and to see how the medicine is working in your body. They will also ask you questions about how you are feeling. There will be a short period while you are taking the medicine and then a period of follow-up after the last dose to ensure everything is well. The total time you would be involved in the study would be explained to you in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is a Phase 1 study?
It's the very first time a new medicine is tested in people. The main aim is to check if it's safe and how the body handles it.
Why is it given by an aerosol?
Giving the medicine as an aerosol means you breathe it in, so it can go directly into your lungs where pneumonia affects you.
Will I know if I'm getting the real medicine?
This is a 'single-blind' study, meaning you won't know if you're getting the active medicine or a dummy treatment (placebo), but the study doctors will know.
What is 'immune activation'?
It means the study is looking at whether the medicine helps to switch on or boost your body's natural defences (immune system) in your lungs to fight the infection.
Can children take part in this study?
No, this study is only for adults aged 18 and over.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.